Stocks · Health care · Pharmaceutical Preparations

Schrodinger, Inc.

SDGR Clue Score56
United States Fiscal year ends December CIK 0001490978 Results filed 4 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Karen Akinsanya
17 Sep 2026
See Remarks
Sold after exercise
21,599
$30.00
$647.97K
Karen Akinsanya
17 Sep 2026
See Remarks
Sold after exercise
10,000
$28.00
$280.00K
Ramy Farid
17 Apr 2026
President & CEO
Sold after exercise
43,000
$12.21
$524.94K
Ramy Farid
16 Apr 2026
President & CEO
Sold after exercise
43,000
$12.33
$530.23K
Karen Akinsanya
14 Apr 2025
President of R&D, Therapeutics
Sold after exercise
3,345
$25.00
$83.63K
Karen Akinsanya
14 Apr 2025
President of R&D, Therapeutics
Sold after exercise
5,000
$25.11
$125.55K
Karen Akinsanya
14 Apr 2025
President of R&D, Therapeutics
Sold after exercise
8,378
$25.11
$210.39K
Yvonne Tran
18 Feb 2025
EVP, CLO & Cpo
Sold after exercise
3,902
$28.00
$109.26K
Yvonne Tran
30 Jun 2023
EVP, CLO & Cpo
Sold after exercise
12,040
$50.00
$602.00K
Yvonne Tran
23 May 2023
EVP, CLO & Cpo
Sold after exercise
7,960
$40.01
$318.46K
Nancy Thornberry
22 May 2023
Director
Sold after exercise
14,850
$35.00
$519.75K
Yvonne Tran
22 May 2023
EVP, CLO & Cpo
Sold after exercise
15,000
$35.04
$525.63K
Yvonne Tran
2 Feb 2023
EVP & Chief Legal Officer
Sold after exercise
25,000
$27.26
$681.38K
Ramy Farid
4 Jan 2023
President & CEO
Sold after exercise
66,886
$18.28
$1.22M
Nancy Thornberry
11 Aug 2022
Director
Sold after exercise
4,950
$35.00
$173.25K
Robert Lorne Abel
13 Dec 2021
See Remarks
Sold after exercise
1,900
$36.88
$70.08K
Robert Lorne Abel
13 Dec 2021
See Remarks
Sold after exercise
13,701
$36.20
$495.91K
Karen Akinsanya
15 Oct 2021
See Remarks
Sold after exercise
1,393
$55.75
$77.66K
Karen Akinsanya
15 Sep 2021
See Remarks
Sold after exercise
1,394
$61.13
$85.22K
Robert Lorne Abel
13 Sep 2021
See Remarks
Sold after exercise
9,782
$62.14
$607.90K
Robert Lorne Abel
13 Sep 2021
See Remarks
Sold after exercise
5,820
$61.09
$355.54K
Joel Lebowitz
2 Sep 2021
EVP & CFO
Sold after exercise
3,874
$64.62
$250.35K
Joel Lebowitz
1 Sep 2021
EVP & CFO
Sold after exercise
1,700
$64.53
$109.70K
Karen Akinsanya
16 Aug 2021
See Remarks
Sold after exercise
16,047
$58.17
$933.53K
Karen Akinsanya
16 Aug 2021
See Remarks
Sold after exercise
21,691
$57.43
$1.25M
Joel Lebowitz
14 Jul 2021
EVP & CFO
Sold after exercise
305
$69.45
$21.18K
Joel Lebowitz
14 Jul 2021
EVP & CFO
Sold after exercise
2,762
$68.35
$188.79K
Joel Lebowitz
14 Jul 2021
EVP & CFO
Sold after exercise
2,507
$67.53
$169.30K
Robert Lorne Abel
21 Jun 2021
See Remarks
Sold after exercise
15,602
$74.16
$1.16M
Joel Lebowitz
14 Jun 2021
EVP & CFO
Sold after exercise
200
$78.60
$15.72K
Joel Lebowitz
14 Jun 2021
EVP & CFO
Sold after exercise
3,281
$77.82
$255.32K
Joel Lebowitz
14 Jun 2021
EVP & CFO
Sold after exercise
2,093
$76.53
$160.18K
Karen Akinsanya
8 Jun 2021
See Remarks
Sold after exercise
800
$76.08
$60.86K
Karen Akinsanya
8 Jun 2021
See Remarks
Sold after exercise
9,442
$75.49
$712.78K
Karen Akinsanya
7 Jun 2021
See Remarks
Sold after exercise
6,479
$75.10
$486.57K
Rosana Kapeller-Libermann
7 Jun 2021
Director
Sold after exercise
1,000
$75.00
$75.00K
Joel Lebowitz
18 May 2021
EVP & CFO
Sold after exercise
5,574
$64.45
$359.24K
Robert Lorne Abel
5 May 2021
See Remarks
Sold after exercise
954
$71.02
$67.75K
Robert Lorne Abel
5 May 2021
See Remarks
Sold after exercise
8,490
$69.97
$594.07K
Robert Lorne Abel
5 May 2021
See Remarks
Sold after exercise
6,429
$68.97
$443.42K
Joel Lebowitz
14 Apr 2021
EVP & CFO
Sold after exercise
16
$79.73
$1.28K
Joel Lebowitz
14 Apr 2021
EVP & CFO
Sold after exercise
1,498
$79.08
$118.47K
Joel Lebowitz
14 Apr 2021
EVP & CFO
Sold after exercise
3,860
$78.26
$302.07K
Joel Lebowitz
14 Apr 2021
EVP & CFO
Sold after exercise
200
$76.91
$15.38K
Showing 250 of 728 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 289
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 38
Sales on a Rule 10b5-1 plan 28
Sales straight out of an exercise 176
Sales at will 508
Transactions with no price 0
Shares from compensation/vesting 31,609,483
Sales filed before the plan box existed 505
History held since 10 Feb 2020